Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
On Wednesday, Scotiabank (TSX:BNS) analysts lowered their rating on Myriad Genetics (NASDAQ:MYGN) stock from ’Sector Outperform’ to ’Sector Perform’, significantly reducing the price target to $6.00 from the previous $20.00. The revision reflects a cautious stance towards the company’s near-term prospects. According to InvestingPro data, the stock has declined over 81% in the past year, with 13 analysts recently revising their earnings expectations downward.
Myriad Genetics, a company specializing in molecular diagnostics with a market capitalization of $392 million, is undergoing a period that analysts believe will be transitional for the year 2025. Despite maintaining a healthy gross margin of 70%, InvestingPro analysis indicates the company is not currently profitable, with negative earnings in the last twelve months. The analysts at Scotiabank have expressed a desire to observe concrete and consistent progress within the company’s Oncology and Women’s Health segments before adopting a more optimistic view of the stock.
The downgrade comes as Myriad Genetics prepares to navigate strategic changes under new leadership. The company’s new CEO is expected to implement a strategy reset, which has prompted Scotiabank to adopt a wait-and-see approach to the stock. With a beta of 2.02, the stock shows significantly higher volatility than the broader market, which may present both risks and opportunities for investors. For deeper insights into Myriad Genetics’ valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports.
The lowered price target of $6.00 represents a significant reduction and indicates a more conservative expectation of the company’s stock performance. The analysts’ decision to downgrade the rating to ’Sector Perform’ suggests that they anticipate Myriad Genetics to perform in line with the overall sector, as opposed to outperforming its peers.
Scotiabank’s revised outlook for Myriad Genetics stock is based on the premise that the company will need to demonstrate sustained progress in its strategic business areas. The analysts have underscored the importance of consistent advancements in order to become more positive on the company’s shares in the future.
In other recent news, Myriad Genetics reported first-quarter 2025 revenue of $196 million, falling short of the $200.9 million forecast, marking a 3% year-over-year decline. The company also missed earnings per share (EPS) expectations, which contributed to a challenging financial outlook. Jefferies responded to these results by cutting Myriad Genetics’ stock target from $11.00 to $5.00 while maintaining an Underperform rating. The firm’s analysis pointed out the company’s lower guidance by $35 million at the midpoint, attributing it to underperformance in its Genesight and HCT products. Furthermore, the EPS projection was downgraded to breakeven from an anticipated $0.09, partly due to a $10 million negative impact from a UnitedHealth Group (NYSE:UNH) policy change. Despite these setbacks, Myriad Genetics achieved a 50 basis point increase in gross margin, reaching 69%, and reduced operational expenses by $25 million. The company has updated its full-year 2025 revenue guidance to between $787 million and $823 million, with an adjusted EBITDA target of $19 million to $27 million. Analysts have highlighted ongoing challenges, including CEO transition and cash flow issues, as Myriad Genetics navigates these operational headwinds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.